Mika Aoyagi-Scharber

Energizer
DISC Type : I

Vice President, Translational Research, Program & Portfolio Management at Ultragenyx

San Francisco, California, United States

Overview

Mika Aoyagi-Scharber is the Vice President of Translational Research at Ultragenyx, leading program and portfolio management. Her career includes extensive experience in scientific strategy at BioMarin. She holds a Ph. D. from Scripps Research and is described by colleagues as inquisitive, thorough, and hard-working.

While specific personal hobbies are not public, she maintains a strong connection to her alma maters, the University of Minnesota and Scripps Research, indicating a passion for the academic and scientific communities that shaped her career.

She is a co-inventor on a patent for compositions and methods for treating the rare Glycogen Storage Disease Type III.

Personality Overview

Imaginative

Informal

Believer

They are friendly, approachable and love to make new connections.  Unlike C or D types, they are vocal with their opinions but not so much with their questions. They are not always early adopters but can be pursuaded by leveraging strong relationships.

Topics They Care About

Rare Disease Therapeutics
Her career at both Ultragenyx and BioMarin, along with a patent for treating Glycogen Storage Disease Type III, shows a deep commitment to developing therapies for rare disorders.
Translational Research
Her executive title and focus involve bridging the gap between foundational scientific discoveries and creating tangible new treatments for patients.
Gene Therapy
She co-authored recent research on a non-viral gene therapy approach for treating Infantile Neuroaxonal Dystrophy, a rare pediatric disorder.

Media Appearances

Mika has no verified media appearances

Work History

9-2024
Vice President, Translational Research, Program & Portfolio Management at Ultragenyx
4-2021 - 8-2024
Executive Director, Translational Research, Program & Portfolio Management at Ultragenyx
3-2021 - 4-2021
Executive Director, Scientific Strategy & Discovery Portfolio at BioMarin Pharmaceutical Inc.
4-2018 - 2-2021
Senior Director, Scientific Strategy & Discovery Portfolio at BioMarin Pharmaceutical Inc.
11-2017 - 3-2018
Director, Scientific Strategy & Discovery Portfolio at BioMarin Pharmaceutical Inc.

Education

1998 - 2004
Ph.D. from Scripps Research
1993 - 1997
B.S. from University of Minnesota

More Information

Social Presence :

Prographics :

Exp : 21 Location : San Francisco, California, United States Job Level : Senior Designation : Vice President, Translational Research, Program & Portfolio Management at Ultragenyx
URL has been copied!

Insights For Selling To Mika

During A Call Or A Meeting

DO's

  • Invite them for a lunch or a drink/coffee
  • Talk anecdotally about the customer experience that your product offers
  • Use adjectives like ‘amazing’, ‘coolest’, ‘unbelievable’ etc.

DONT's

  • Don’t push them to make a decision too fast, let them get comfortable first
  • Avoid ifs and buts, don’t talk too much about the risks etc.
  • Don’t assume a yes just because they have not said no

When Cold Calling

When Writing An Email

While Negotiating & Closing

    The secret to closing fast with Mika is

  • Relationship and rapport can play an important role, sometimes more than the other factors.
  • Will you ever get a clear answer from Mika

  • They will probably never say no directly, you have to make that decision yourself.

Insights For Deal Planning

    How fast (or slow) will Mika move?

  • They are not the quickest decision makers, their friendly attitude could be misleading.
  • Can Mika take some risk or not?

  • They can accept limited risks, ones that they think will not impact them personally.

You And Mika

Personality Compatibility


Other Ultragenyx Employees

Explore more public profiles from related professionals at the same organization.

More Profiles

Discover additional public profiles from our index.

Search more profiles

Looking for someone else? Search here for anyone.

Or visit Humantic AI to know more.